Company · CIK 0001411906 · SIC 2834 — Pharmaceutical Preparations
Ampio Pharmaceuticals, Inc. · AMPE
Insider activity reported against this company. All insider holders · Files at: AYTU. On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2019 AForm 4 → | Jan 4, 4:44 pm EST | David R StevensDirector | 45,454 | $0.44 | $20,000 | 86,990 | — | plan? |
| Jan 2, 2019 AForm 4 → | Jan 4, 4:44 pm EST | Richard B GilesDirector | 45,454 | $0.44 | $20,000 | 267,294 | — | plan? |
| Jan 2, 2019 AForm 4 → | Jan 4, 4:43 pm EST | Philip H CoelhoDirector | 45,454 | $0.44 | $20,000 | 155,928 | — | plan? |
| Jan 25, 2018 AForm 4 → | Jan 29, 5:10 pm EST | David R StevensDirector | 5,747 | $3.48 | $20,000 | 41,536 | — | plan? |
| Jan 25, 2018 AForm 4 → | Jan 29, 5:09 pm EST | Richard B GilesDirector | 5,747 | $3.48 | $20,000 | 221,840 | — | plan? |
| Jan 25, 2018 AForm 4 → | Jan 29, 5:08 pm EST | Philip H CoelhoDirector | 5,747 | $3.48 | $20,000 | 110,474 | — | plan? |
| Sep 27, 2017 PForm 4 → | Sep 28, 5:15 pm EDT | Philip H CoelhoDirector | 10,000 | $0.627 | $6,270 | 104,727 | +10.6% | plan? |
| Sep 20, 2017 PForm 4 → | Sep 22, 6:56 pm EDT | Philip H CoelhoDirector | 4,000 | $0.598 | $2,392 | 94,727 | +4.41% | plan? |
| Sep 19, 2017 PForm 4 → | Sep 21, 3:30 pm EDT | Philip H CoelhoDirector | 15,000 | $0.5679 | $8,519 | 90,727 | +19.8% | plan? |
| Sep 5, 2017 PForm 4/A → | Sep 7, 11:06 am EDT | Philip H CoelhoDirector | 30,000 | $0.5592 | $16,776 | 75,727 | +65.6% | plan? |
| Sep 5, 2017 PForm 4 → | Sep 6, 9:18 pm EDT | Philip H CoelhoDirector | 30,000 | $0.5592 | $16,776 | 75,727 | — | plan? amended |
| Jan 3, 2017 AForm 4 → | Jan 5, 4:20 pm EST | David R StevensDirector | 20,826 | $0.9603 | $19,999 | 35,789 | — | plan? |
| Jan 3, 2017 AForm 4 → | Jan 5, 4:19 pm EST | Richard B GilesDirector | 20,826 | $0.9603 | $19,999 | 216,093 | — | plan? |
| Jan 3, 2017 AForm 4 → | Jan 5, 4:19 pm EST | Philip H CoelhoDirector | 20,826 | $0.9603 | $19,999 | 45,727 | — | plan? |
| Jan 4, 2016 AForm 4 → | Jan 6, 6:26 pm EST | David R StevensDirector | 6,042 | $3.31 | $19,999 | 14,963 | — | plan? |
| Jan 4, 2016 AForm 4 → | Jan 6, 6:24 pm EST | Richard B GilesDirector | 6,042 | $3.31 | $19,999 | 195,267 | — | plan? |
| Jan 4, 2016 AForm 4 → | Jan 6, 6:22 pm EST | Philip H CoelhoDirector | 6,042 | $3.31 | $19,999 | 24,901 | — | plan? |
| Jan 2, 2015 AForm 4 → | Jan 6, 4:50 pm EST | David R StevensDirector | 2,666 | $3.75 | $9,998 | 8,921 | — | plan? |
| Jan 2, 2015 AForm 4 → | Jan 6, 4:48 pm EST | Philip H CoelhoDirector | 2,666 | $3.75 | $9,998 | 18,859 | — | plan? |
| Jan 2, 2015 AForm 4 → | Jan 6, 4:47 pm EST | Richard B GilesDirector | 2,666 | $3.75 | $9,998 | 189,225 | — | plan? |
| Feb 25, 2014 JForm 5 → | Feb 23, 2015, 6:32 pm EST | Vaughan Lennox CliftChief Regulatory Affairs | 522,200 | $8.02 | $4,188,044 | 0 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2018 AForm 4 → | Jan 9, 2019, 4:15 pm EST | David R StevensDirector | 30,000 | — | — | 30,000 | — | late |
| Dec 15, 2018 AForm 4 → | Jan 9, 2019, 4:13 pm EST | Richard B GilesDirector | 30,000 | — | — | 30,000 | — | late |
| Dec 15, 2018 AForm 4 → | Jan 9, 2019, 4:12 pm EST | Philip H CoelhoDirector | 30,000 | — | — | 30,000 | — | late |
| Oct 1, 2018 ADForm 4 → | Oct 2, 5:29 pm EDT | III Thomas E. ChilcottChief Financial Officer | 150,000 | — | — | 75,000 | — | |
| Oct 1, 2018 ADForm 4 → | Oct 2, 5:27 pm EDT | Holli CherevkaChief Operating Officer | 578,804 | — | — | 9,402 | — | |
| Sep 20, 2018 AForm 4 → | Sep 24, 5:02 pm EDT | III Thomas E. ChilcottChief Financial Officer | 75,000 | — | — | 75,000 | — | |
| Sep 23, 2017 AForm 4 → | Sep 28, 5:17 pm EDT | David R StevensDirector | 30,000 | — | — | 30,000 | — | late |
| Sep 23, 2017 AForm 4 → | Sep 28, 5:16 pm EDT | Richard B GilesDirector | 30,000 | — | — | 30,000 | — | late |
| Sep 23, 2017 AForm 4 → | Sep 28, 5:15 pm EDT | Philip H CoelhoDirector | 30,000 | — | — | 30,000 | — | late |
| Aug 28, 2017 AForm 4 → | Aug 30, 6:19 pm EDT | David Bar-OrChief Scientific Officer, Director | 133,000 | — | — | 133,000 | — | |
| Aug 23, 2017 AForm 4 → | Aug 29, 6:51 pm EDT | III Thomas E. ChilcottChief Financial Officer | 200,000 | — | — | 200,000 | — | late |
| Mar 9, 2017 AForm 4 → | Mar 13, 5:31 pm EDT | Michael MacalusoChief Executive Officer, Director | 400,000 | — | — | 400,000 | — | |
| Jan 7, 2017 AForm 4 → | Jan 9, 4:06 pm EST | David R StevensDirector | 30,000 | — | — | 30,000 | — | |
| Jan 7, 2017 AForm 4 → | Jan 9, 4:05 pm EST | Richard B GilesDirector | 30,000 | — | — | 30,000 | — | |
| Jan 7, 2017 AForm 4 → | Jan 9, 4:05 pm EST | Philip H CoelhoDirector | 30,000 | — | — | 30,000 | — | |
| Jul 15, 2016 AForm 4 → | Jul 19, 4:08 pm EDT | Gregory A GouldChief Financial Officer | 150,000 | — | — | 416,666 | — | |
| Dec 12, 2015 AForm 4 → | Dec 15, 5:46 pm EST | David R StevensDirector | 30,000 | — | — | 30,000 | — | |
| Dec 12, 2015 AForm 4 → | Dec 15, 5:45 pm EST | Richard B GilesDirector | 30,000 | — | — | 30,000 | — | |
| Dec 12, 2015 AForm 4 → | Dec 15, 5:43 pm EST | Philip H CoelhoDirector | 30,000 | — | — | 30,000 | — | |
| Aug 3, 2015 AForm 4 → | Aug 3, 8:13 pm EDT | David Bar-OrChief Scientific Officer, Director | 300,000 | — | — | 300,000 | — | |
| Jul 31, 2015 AForm 4 → | Aug 3, 8:12 pm EDT | Vaughan Lennox CliftChief Regulatory Affairs | 170,000 | — | — | 170,000 | — | |
| Jul 30, 2015 AForm 4 → | Aug 3, 8:11 pm EDT | Gregory A GouldChief Financial Officer | 100,000 | — | — | 100,000 | — |
Filed by this entity as an insider elsewhere — common stock
| Trade | Reported (ET) | Company | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2015 JForm 4 → | Dec 3, 10:05 am EST | AYTU BIOSCIENCE, INCAYTU | 10,399,661 | — | — | 1,226,407 | — | plan? |
Filed by this entity as an insider elsewhere — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.